



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, August 26, 2019

In accordance with Article 17 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and Article 226 of the recast Spanish Securities Market Act (*Ley del Mercado de Valores*), the following **RELEVANT EVENT** is hereby reported:

Pharma Mar, S.A. and Janssen Products, LP (“Janssen”) have entered into a new Licensing Agreement, which replaces the 2001 Licensing Agreement (Relevant Event number 30692 submitted by Zeltia, S.A. (absorbed company) on September 25, 2001), under which Janssen retains the right to sell and distribute, on an exclusive basis, Yondelis[®] and any other product containing the active substance (trabectedin) in the United States. The milestones and royalties on Janssen’s U.S. net sales of the product remain the same as in the 2001 Licensing Agreement. Pharma Mar will maintain the exclusive production rights of active ingredient, which will be supplied to Janssen for clinical and commercial use.

Simultaneously, Pharma Mar and Janssen have entered into a Master Product Transfer Agreement, under which Janssen will transfer to Pharma Mar all Janssen’s rights to the compound in the rest of the countries previously licensed to Janssen. This includes all countries of the world with the exception of U.S., Europe and Japan, the last being licensed to Taiho Pharmaceuticals Co. Ltd. The implementation of this transfer agreement will take place gradually depending on the specific regulatory requirements of each country. Janssen will continue to sell the product until the transfer of the marketing authorizations to Pharma Mar is complete. Pharma Mar plans to market Yondelis[®] through local partners in the transferred territories.

Please find attached press release that will be distribute to the media.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com



PharmaMar enters into a new licensing agreement with Janssen for Yondelis®

- Janssen will retain rights to exclusively market and distribute Yondelis® and any other product containing its active substance in the United States
- The new agreement will enable PharmaMar to distribute Yondelis® in more than 40 countries where the product has already been approved

Madrid, August 26th, 2019. - PharmaMar (MSE:PHM) has entered into a new Licensing Agreement with Janssen Products, LP (Janssen) for Yondelis® (trabectedin), which replaces the 2001 Licensing Agreement entered into by both parties.

Under this new Licensing Agreement, Janssen will retain the right to sell and distribute, on an exclusive basis, Yondelis® and any other product containing its active substance in the United States (U.S.). Both companies may agree to share new product research. The milestones and royalties on Janssen's U.S. net sales of the product remain the same as in the 2001 Licensing Agreement.

PharmaMar will maintain the exclusive production rights of active ingredient trabectedin, which will be supplied to Janssen for clinical and commercial use.

Simultaneously, PharmaMar and Janssen have entered into a Master Product Transfer Agreement (MPTA), under which Janssen will transfer to PharmaMar all of Janssen's rights to the compound in the rest of the countries previously licensed to Janssen. This includes all countries of the world with the exception of U.S., Europe and Japan, the last being licensed and marketed by Taiho Pharmaceuticals Co. Ltd.

The implementation of this transfer agreement will take place gradually depending on the specific regulatory requirements of each country. PharmaMar, together with Janssen, is committed to ensuring the supply of Yondelis® during the transfer. Janssen will continue to sell the product until the transfer of the marketing authorizations to PharmaMar are complete.

This MPTA will enable PharmaMar to distribute Yondelis® in more than 40 additional countries where the product has already been approved. PharmaMar plans to market Yondelis® through local partners and does not rule out the possibility of new

applications, and health regulatory submissions and approvals in more countries where the product is not currently approved.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About Yondelis®

Yondelis® (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from *Ecteinascidia turbinata*, a type of sea squirt. Yondelis® exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000

Investor Relations:

José Luis Moreno Martínez-Losa – Capital Markets & Investor Relations Director
investorrelations@pharmamar.com
Phone: +34 914444500



Or please visit our website at www.pharmamar.com